BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore

BridgeBio Pharma, Inc. remains a Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics. Learn more ...

Is Attruby’s Accelerating Launch and Star-Studded Awareness Campaign Altering The Investment Case For BridgeBio Pharma (BBIO)?

BridgeBio Pharma recently reported a strong and accelerating launch of its heart drug Attruby, with rapid growth in unique patient prescriptions and prescribers, supported by compelling clinical ...
Fierce Pharma

Pfizer’s victory in delaying Vyndamax generics is mixed bag for BridgeBio: analysts

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

Pfizer protects $6.4bn heart disease blockbuster from generics, for now

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update)

BridgeBio (BBIO) rose 6.6% after a court filing disclosed a settlement in a generic patent case over Pfizer's (PFE) Vyndamax ...
Insider Monkey

UBS Reaffirms Buy on BridgeBio (BBIO) With Optimism Around Attruby Launch

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks among the best biotech stocks to buy. UBS reaffirmed its Buy rating for BridgeBio Pharma, Inc. (NASDAQ:BBIO) on September 22, citing the company’s Attruby ...
BioSpace

Pfizer settles with generic drugmakers to protect blockbuster drug until 2031

The settlements delay the entry of generic copies of Pfizer’s Vyndamax by almost three years, stabilizing sales of a drug ...
Nasdaq

BridgeBio Pharma Secures $300 Million in Royalty Financing to Support Attruby® Launch and Late-Stage Programs

BridgeBio Pharma has secured a $300 million upfront payment through a royalty financing agreement with HealthCare Royalty and Blue Owl Capital, which will bolster its financial position and support ...
Seeking Alpha

BridgeBio Pharma: Betting Big On Rare Disease Catalysts

Acoramidis (Attruby) shows strong clinical data and rapid launch, but faces tough competition from Pfizer’s tafamidis and upcoming RNAi drugs. BBIO’s pipeline is diverse with multiple late-stage ...
BioPharma Dive

Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.

Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, ...
Hosted on MSN

Pfizer settles to delay Vyndamax generics until 2031

Pfizer has reached settlements with three generic drugmakers, pushing back U.S. market entry of Vyndamax copies until mid-2031, pending other litigation. The move preserves billions in annual revenue ...
Insider Monkey

14 Best Biotech Stocks to Buy Right Now

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks among the best biotech stocks to buy. UBS reaffirmed its Buy rating for BridgeBio Pharma, Inc. (NASDAQ:BBIO) on September 22, citing the company’s Attruby ...